Listed

PharmaCyte Biotech, Inc.: Form 10-K for the period ended Apr 30, 2013

Filed with the SEC on Jul 29, 2013 and accepted by EDGAR at Jul 29, 2013, 16:18 ET.

Share

Sections

The sections of this filing are being extracted from EDGAR and appear here in about a minute. Meanwhile, read the original on sec.gov. The main document on sec.gov.

Figures reported in this filing

Standardized line items from the XBRL in this filing, for the period ended 2013-04-30. Comparative periods it repeats are left out.

Figures reported in this filing
Line itemPeriodValueXBRL concept
Revenue12 months2012-05-01 to 2013-04-30$12.2kus-gaap:Revenues
Cost of revenue12 months2012-05-01 to 2013-04-30$9.6kus-gaap:CostOfRevenue
Gross profit12 months2012-05-01 to 2013-04-30$2.5kus-gaap:GrossProfit
Operating income12 months2012-05-01 to 2013-04-30−$1.7mus-gaap:OperatingIncomeLoss
Interest expense12 months2012-05-01 to 2013-04-30$112.7kus-gaap:InterestExpense
Net income12 months2012-05-01 to 2013-04-30−$1.6mus-gaap:NetIncomeLoss
Basic EPS12 months2012-05-01 to 2013-04-30$0.00us-gaap:EarningsPerShareBasic
Operating cash flow12 months2012-05-01 to 2013-04-30−$390.4kus-gaap:NetCashProvidedByUsedInOperatingActivities
Cash and equivalentsAt period end2013-04-30$199.3kus-gaap:CashAndCashEquivalentsAtCarryingValue
Current assetsAt period end2013-04-30$1.8mus-gaap:AssetsCurrent
Total assetsAt period end2013-04-30$2.9mus-gaap:Assets
Current liabilitiesAt period end2013-04-30$3.8mus-gaap:LiabilitiesCurrent
Total liabilitiesAt period end2013-04-30$3.8mus-gaap:Liabilities
Shareholders' equityAt period end2013-04-30−$1.5mus-gaap:StockholdersEquity

Source: SEC EDGAR, the filing index for accession 0001157075-13-000010. Last ingested by Listed: Nov 14, 2026, 20:52 ET. Listed shows no prices and gives no investment advice.